Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Biomarkers in Immuno-oncology

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Biomarkers in Immuno-oncology
  •  
  • Permission not
    granted for presentation
  •  
  •  
Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors
Jordi Rodon
Vall d’Hebron University Hospital and Universitat Autònoma de Barcelona, Barcelona, Spain
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Effect of JAK/STAT or PI3Kδ plus PD-1 inhibition on the tumor microenvironment: Biomarker results from a phase Ib study in patients with advanced solid tumors
John M Kirkwood
UPMC Hillman Cancer Center Melanoma and Skin Cancer Program, Pittsburgh, PA, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Aung Naing
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275
Padmanee Sharma
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Anthony W. Tolcher
START, San Antonio, TX, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
Lillian L Siu
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma
Alexander C Huang
University Of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
Biomarkers in Immuno-oncology
The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i
Reinhard Dummer
University Hospital Zürich, Zürich, Switzerland
from AACR Annual Meeting 2018 on April 17, 2018 2:45 PM-5:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8